Cargando…
Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells
OBJECTIVES: Oestrogen plays a key role in the development of breast malignancies. Therefore, aromatase inhibitors (e.g. letrozole [LTZ]) are widely used in the treatment of breast cancer. On the other hand, oestrogen is important to the integrity of bone mass. Research has shown that zoledronic acid...
Autores principales: | Sheweita, Salah A., Ammar, Rania G., Sabra, Sally A., Sultan, Ahmed S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taibah University
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858005/ https://www.ncbi.nlm.nih.gov/pubmed/33603639 http://dx.doi.org/10.1016/j.jtumed.2020.10.017 |
Ejemplares similares
-
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014) -
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010) -
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016) -
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001) -
A Case of Pseudogout Following Zoledronic Acid Administration
por: Hill, Alexander C, et al.
Publicado: (2021)